ANDA Sponsors Fail To Knock Out Trintellix Active Ingredient Patent

IP Expiring In June 2026 Upheld As Valid By US District Court

 
• By Dean Rudge
  
Gavel
Trintellix was the first treatment for acute major depressive disorder approved by the FDA • Source: Shutterstock

More from Generics

More from Products